7 results on '"Stuhler G"'
Search Results
2. What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?
- Author
-
Ringdén, O., Labopin, M., Sadeghi, B., Mailhol, A., Beelen, D., Fløisand, Y., Ghavamzadeh, A., Finke, J., Ehninger, G., Volin, L., Socié, G., Kröger, N., Stuhler, G., Ganser, A., Schmid, C., Giebel, S., Mohty, M., and Nagler, A.
- Subjects
- *
GRAFT versus host disease , *GRAFT versus host reaction , *HOMOGRAFTS , *HEMATOPOIETIC stem cell transplantation , *HEMATOPOIETIC stem cells , *ACUTE myeloid leukemia treatment , *LYMPHOBLASTIC leukemia treatment , *IMMUNOSUPPRESSIVE agents , *COMPARATIVE studies , *IMMUNOSUPPRESSION , *LYMPHOBLASTIC leukemia , *RESEARCH methodology , *MEDICAL cooperation , *PROGNOSIS , *RESEARCH , *SURVIVAL analysis (Biometry) , *DISEASE relapse , *EVALUATION research , *TREATMENT effectiveness - Abstract
Background: Acute graft-versus-host disease (aGVHD) is a major complication of allogeneic haematopoietic stem cell transplantation (HSCT). With new promising therapies, survival may improve for severe aGVHD.Objectives: We wanted to analyze the long-term outcome in patients who survive severe aGVHD.Methods: This study was a landmark analysis of 23 567 patients with acute Leukaemia who survived for more than 6 months after HSCT, 2002-2014. Patients alive after severe aGVHD (n = 1738) were compared to controls.Results: Patients with severe aGVHD had higher non-relapse mortality (NRM) and higher rate of extensive chronic GVHD (cGVHD) than the controls (P < 10-5 ). The probability of relapse was significantly lower in the severe aGVHD group, but Leukaemia-free survival (LFS) and overall survival were significantly lower than for the controls (P < 10-5 ). Five-year LFS in patients with severe aGVHD was 49%, as opposed to 61% in controls with no or mild GVHD and 59% in patients with moderate GVHD.Conclusions: HSCT patients who survive severe aGVHD have higher risk of developing extensive cGVHD, a higher NRM, a lower relapse probability, and lower LFS than other HSCT patients. This study is a platform for outcome analysis in patients treated with novel therapies for acute GVHD. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
3. Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning.
- Author
-
Casper, J, Holowiecki, J, Trenschel, R, Wandt, H, Schaefer-Eckart, K, Ruutu, T, Volin, L, Einsele, H, Stuhler, G, Uharek, L, Blau, I, Bornhaeuser, M, Zander, A R, Larsson, K, Markiewicz, M, Giebel, S, Kruzel, T, Mylius, H A, Baumgart, J, and Pichlmeier, U
- Subjects
- *
FLUDARABINE , *TREATMENT effectiveness , *ACUTE myeloid leukemia treatment , *GRAFT versus host disease , *HEMATOPOIETIC stem cell transplantation - Abstract
An alternative reduced-toxicity conditioning regimen for allogeneic transplantation, based on treosulfan and fludarabine, has recently been identified. The safety and efficacy of this new conditioning regimen has been investigated prospectively in patients with AML. A total number of 75 patients with AML in CR were treated with 3 × 14 g/m2 treosulfan and 5 × 30 mg/m2 fludarabine, followed by matched sibling or unrelated SCT. Patients were evaluated for engraftment, adverse events, GVHD, and for non-relapse mortality, relapse incidence, overall and disease-free survival (DFS). All patients showed primary engraftment of neutrophils after a median of 20 days. Non-hematological adverse events grade III-IV in severity included mainly infections (59%) and gastrointestinal symptoms (7%). Acute GVHD grade II-IV occurred in 21% and extensive chronic GVHD occurred in 16% of the patients. After a median follow-up of 715 days, the 2-year overall and DFS estimates were 61% and 55%, respectively. The 2-year incidences of relapse and non-relapse mortality reached 34% and 11%, respectively. In summary, our data confirm promising safety and efficacy of the treosulfan-based conditioning therapy in AML patients, ClinicalTrials.gov Identifier: NCT01063660. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
4. Endophthalmitis as primary clinical manifestation of fatal fusariosis in an allogeneic stem cell recipient.
- Author
-
Kapp, M., Schargus, M., Deuchert, T., Springer, J., Wendel, F., Loeffler, J., Grigoleit, G.U., Kurzai, O., Heinz, W., Einsele, H., and Stuhler, G.
- Subjects
- *
CASE studies , *FUSARIOSIS , *STEM cells , *FUSARIUM solani , *ANTIFUNGAL agents , *ACUTE myeloid leukemia , *CANCER chemotherapy , *LEUKEMIA - Abstract
M. Kapp, M. Schargus, T. Deuchert, J. Springer, F. Wendel, J. Loeffler, G.U. Grigoleit, O. Kurzai, W. Heinz, H. Einsele, G. Stuhler. Endophthalmitis as primary clinical manifestation of fatal fusariosis in an allogeneic stem cell recipient. Transpl Infect Dis 2011: 13: 374-379. All rights reserved Abstract: The occurrence of infections due to previously rare opportunistic pathogens is increasing despite the use of novel treatment strategies for immunocompromised patients. Here, we report the case of a patient presenting with fever, muscle pain, and bilateral endophthalmitis after allogeneic hematopoietic stem cell transplantation. Fusarium solani was isolated from peripheral blood samples and identified as the cause of gradual bilateral vision loss, despite appropriate antifungal prophylaxis, and therapy including vitrectomy and intraocular instillation of antifungal agents. The patient became comatose; basal meningitis involving both optic nerves was suspected based on magnetic resonance tomography. The patient died 8 days later due to septic multi-organ failure. Autopsy revealed that both kidneys, but no other organs, were infiltrated by Fusarium. No fungus was found in cerebral tissues or cerebrospinal fluid. Our case demonstrates some of the typical clinical features of systemic fusariosis and its potentially fatal outcome. The clinical observations reported here may help clinicians caring for immunocompromised patients to accelerate diagnosis and initiate treatment early at the onset of this fatal complication, and highlight the urgent need for interdisciplinary management of invasive fusariosis. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
5. CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT.
- Author
-
Kapp, M., Stevanović, S., Fick, K., Tan, S. M., Loeffler, J., Opitz, A., Tonn, T., Stuhler, G., Einsele, H., and Grigoleit, G. U.
- Subjects
- *
IMMUNOREGULATION , *PROTEINASES , *CELLULAR immunity , *T cells , *TUMOR markers , *STATISTICAL correlation , *THERAPEUTICS - Abstract
The GVL effect following allo-SCT is one of the most prominent examples showing the ability of the immune system to eliminate malignant hematological diseases. Tumor-associated Ags (TAA), for instance WT1 and proteinase-3, have been proposed as targets for T cells to establish a GVL effect. Here, we examined an additional TAA (MUC1) as a possible T-cell target of GVL-related immune responses. We have defined new peptide epitopes from the MUC1 Ag to broaden patients’ screening and to expand the repertoire of immunologic monitoring as well as for therapeutic approaches in the future. Twenty-eight patients after allo-SCT have been screened for T-cell responses toward TAA (proteinase-3, WT1, MUC1). We could detect a significant relationship between relapse and the absence of a TAA-specific T-cell response, whereby only 2/13 (15%) patients with TAA-specific CTL relapsed, in contrast to 9/15 (60%) patients without TAA-specific CTL responses (P<0.05). In conclusion, CD8+ T-cell responses directed to TAA might contribute to the GVL effect. These observations highlight both the importance and the potential of immunotherapeutic approaches after allo-SCT.Bone Marrow Transplantation (2009) 43, 399–410; doi:10.1038/bmt.2008.426; published online 12 January 2009 [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
6. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma.
- Author
-
Schmidt-Hieber, M., Blau, I. W., Trenschel, R., Andreesen, R., Stuhler, G., Einsele, H., Kanz, L., Keilholz, U., Marinets, O., Beelen, D. W., Fauser, A. A., Volin, L., Ruutu, T., Uharek, L., Fietz, T., Knauf, W., Hopfenmüller, W., Thiel, E., Freund, M., and Casper, J.
- Subjects
- *
MULTIPLE myeloma , *CANCER treatment , *FLUDARABINE , *ALKYLATING agents , *STEM cell transplantation , *GRAFT versus host disease , *PATIENTS , *THERAPEUTICS - Abstract
In recent years, reduced-intensity conditioning (RIC) regimens before allogeneic stem cell transplantation (SCT) are increasingly used in patients not eligible for conventional conditioning. We did a retrospective, multicenter analysis to assess the feasibility of conditioning with fludarabine and treosulfan before allogeneic SCT in multiple myeloma patients. Thirty-four patients with a median age of 51.5 years were included in the analysis. All patients underwent myeloablation after conditioning followed by stable engraftment, and 29 of 31 evaluable patients (94%) showed early complete hematopoietic chimerism. Non-hematological toxicities were limited and encompassed mainly fever in neutropenia and infections. Grade II–IV acute and chronic graft-versus-host disease was observed in 33 and 39%, respectively. With a median follow-up of 708 days (range 60–1729 days), the median progression-free survival was 180 days. The treatment-related mortality was 10% on day 100 and 25% after 1 year. The median overall survival has not yet been reached. Our data indicate that conditioning with fludarabine and treosulfan before allogeneic SCT is feasible in intensively pretreated multiple myeloma patients and leads to stable engraftment and complete hematopoietic chimerism. Randomized trials are warranted to determine if this approach might be incorporated in an algorithm of multiple myeloma treatment.Bone Marrow Transplantation (2007) 39, 389–396. doi:10.1038/sj.bmt.1705605; published online 19 February 2007 [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
7. Disseminated mucormycosis of an immunocompromised multiple myeloma patient: impact of biopsy of extramedullary tumours in refractory multiple myeloma.
- Author
-
Gattenlöhner, S., Unzicker, C., Wörner, S., Stuhler, G., Einsele, H., and Müller-Hermelink, H.
- Subjects
- *
LETTERS to the editor , *MULTIPLE myeloma , *PATIENTS - Abstract
A letter to the editor is presented about the case of a 43-year-old female patients with an anaplastic IgG kappa multiple myeloma (MM).
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.